Dynavax Technologies Corporation (Nasdaq: DVAX) announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE